IACH Program
Thursday, September 22, 2022 All timing in CEST |
|
12:00-13:05 | Treatment decisions in high-risk AML*: what is the ultimate goal? Pre-meeting Industry-supported workshop Chair: Prof. Mohamad Mohty (France) Presenters: Thomas Cluzeau (France), Martin Bornhauser (Germany), Gert Ossenkoppele (The Netherlands), Adriano Venditti (Italy), Thomas Schroeder (Germany)*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodyplasia-related changes (AML-MRC) |
13:05-13:15 | Welcome: Mohamad Mohty, France & Arnon Nagler, Israel |
13:15-15:00 | Session 1 – Plenary Opening |
13:15-13:35 | A revolution in ultra-rare diseases: the example of BPDCN: Naveen Pemmaraju, USA |
13:35-13:55 | How I choose the optimal conditioning for AML: Arnon Nagler, Israel |
13:55-14:15 | How I treat sickle cell anemia: Adetola Kassim, USA |
14:15-14:35 | Clinical implications of novel genomic discoveries in CLL: Catherine Wu, USA |
14:35-15:00 | Panel Discussion |
15:00-16:50 | Session 2 – AML |
15:00-15:20 | How I treat newly diagnosed AML: Jorge Sierra, Spain |
15:20-15:40 | How I treat relapsed AML: Christoph Schmid, Germany |
15:40-16:00 | How I use targeted agents as a maintenance therapy in AML: Tapan Kadia, USA |
16:00-16:20 | Disease monitoring in AML: Christopher Hourigan, USA |
16:20-16:50 | Panel Discussion |
16:50-18:40 | Session 3 – ALL |
16:50-17:10 | How I treat newly diagnosed ALL: Sebastian Giebel, Poland |
17:10-17:30 | How I treat relapsed ALL (excluding CAR T therapy): Elias Jabbour, USA |
17:30-17:50 | CAR T therapy in relapsed ALL: Eolia Brissot, France |
17:50-18:10 | Disease monitoring in ALL: TBA |
18:10-18:30 | Panel Discussion |
18:30-19:00 | Photomodulation for the management of transplant complications Industry-supported presentation Presenter: TBA |
19:00-20:15 | Award Ceremony and Special Session |
19:00-19:15 | Award presentation ceremony – H.J. Khoury and GVHD awards Presenters: Mohamad Mohty, France & Arnon Nagler, Israel |
19:15-19:45 | Award presentation lecture / Keynote lecture I: TBA |
19:45-20:15 | Award presentation lecture / Keynote lecture II: TBA |
Friday, September 23, 2022 All timing in CEST |
|
11:00-12:50 | Session 4 – Multiple myeloma |
11:00-11:20 | Diagnostic work-up of myeloma: Eileen Boyle, USA |
11:20-11:40 | Induction regimens in myeloma: Philippe Moreau, France |
11:40-12:00 | Management of relapsed/ refractory myeloma (excluding CAR T): Maria Victoria Mateos, Spain |
12:00-12:20 | CAR T therapy in relapsed/ refractory myeloma: Mohamad Mohty, France |
12:20-12:50 | Panel Discussion |
12:50-14:40 | Session 5 – Lymphomas |
12:50-13:10 | How I treat high grade B cell lymphomas: Christian Gisselbrecht, France |
13:10-13:30 | How I treat low grade B cell lymphomas: Olivier Hermine, France |
13:30-13:50 | How I treat Hodgkin Lymphomas: Anna Sureda, Spain |
13:50-14:10 | How I treat T cell lymphomas: Ali Bazarbachi, Lebanon |
14:10-14:40 | Panel Discussion |
14:40-16:10 | Pursuit of hepatic VOD management excellence A three-part report industry-supported symposium Chair: Prof. Mohamad Mohty (France) Presenters: Anna Sureda (Spain), Antonio Colecchia (Italy), Daniele Avenoso (UK), Francesca Bonifazi (Italy), Michelle Kenyon (UK), Selim Corbacioglu (Germany), Tony Pagliuca (UK) |
16:10-18:00 | Session 6 – Transplant |
16:10-16:30 | How I prevent relapses after transplant in AML/ MDS: Bipin Savani, USA |
13:30-13:50 | Metabolic complications in hematological cancer survivors: Brian Engelhardt, USA |
16:50-17:10 | Endothelial complications after HCT: Nelson Chao, USA |
17:10-17:30 | Revised post-transplant vaccinations guidelines after transplant: Per Ljungman, Sweden |
17:30-18:00 | Panel Discussion |
19:30-20:00 | Session 7 – Chronic leukemia |
18:00-18:20 | How I diagnose CLL: Robin Foà , Italy |
18:20-18:40 | How I treat CLL: Arnon Kater, Netherlands |
18:40-19:00 | How I treat CML: Giuseppe Saglio, Italy |
19:00-19:20 | Role of CAR T therapy in CLL: Mohamad Kharfan-Dabaja, USA |
19:20-20:00 | Panel Discussion |
Saturday, September 24, 2022 All timing in CEST |
|
11:00-12:50 | Session 8 – MDS/ MPD |
11:00-11:20 | How I classify MDS: Valeria Santini, Italy |
11:20-11:40 | Novel approaches to transplant management of MF: Tania Jain, USA |
11:40-12:00 | How I treat MDS- non- transplant management: Amer Zeidan, USA |
12:00-12:20 | How I treat MDS- transplant management: Ibrahim Yakoub-Agha, France |
12:20-12:50 | Panel Discussion |
12:50-15:00 | Session 9 – Marrow failure syndrome |
12:50-13:10 | How I treat aplastic anemia: Phillip Scheinberg, Brazil |
13:10-13:30 | How I manage VEXAS syndrome: Bhagirathbhai Dholaria, USA |
13:30-13:50 | How I treat hypoplastic MDS: Yogen Saunthararajah, USA |
13:50-14:10 | How I treat large granular lymphocytic leukemia: Jaroslaw Maciejewski, USA |
14:10-14:30 | Panel Discussion |
14:30-15:00 | Keynote lecture III: TBA |
15:00-15:15 | Closing remarks: Mohamad Mohty, France & Arnon Nagler, Israel |